Life sciences & healthcare legal cluster: Hub · Dawn raid · VBP · Hospital AR · Exclusive agency · HGR · Trial injury · CRO/CDMO · Device liability · Labeling · SaMD · Patent linkage · License · FDA WL · MDR/IVDR · Internet hospital · Trade secrets · Pharma ads · Device distribution · Sources · Checklist
What VBP changes in the contract stack
National or provincial volume-based procurement resets price, volume expectations, and sometimes supply obligations. Distribution agreements drafted for pre-VBP margins rarely allocate: who absorbs unsold tender volume, who pays for near-expiry stock, what happens if hospital purchase volumes miss the tender model, and whether exclusivity survives SKU delisting.
Post-award distributor disputes (压货 / 退货)
- Channel stuffing pressure — upstream pushes inventory to hit tender supply metrics; downstream cannot sell through at tender economics.
- Return / exchange fights — quality vs commercial returns; whether tender rules or quality agreements override private contract silence.
- Price protection — claims for inventory revaluation when winning prices undercut existing stock.
- Evidence — keep tender award docs, supply schedules, warehouse receipts, WeChat/email volume instructions, and quality release records.
Bid abandonment, breach & blacklist-type consequences
Abandoning a bid or failing supply after award can trigger liquidated damages, performance-bond loss, and procurement “blacklist” or restricted-bidder consequences under tender rules—sometimes more painful than civil damages. Before walk-away, map administrative/tender sanctions separately from pure contract breach.
Two-invoice and distribution redesign
Two-invoice style reforms compress multi-tier distribution. Restructures that look like “paper CSOs” or pass-through entities create both tax/invoice risk and anti-corruption optics (see dawn raid playbook). Rebuild distribution with substance: logistics, title transfer, and genuine promotion roles.
Exclusive agency termination after policy shock
When exclusivity no longer matches tender winners or hospital formularies, parties rush to terminate. Check: territory and channel definitions, non-compete tails, inventory repurchase, goodwill claims, and whether “policy change” is a true force-majeure/change-in-law clause or just commercial regret. Device-specific GTM background: device distribution & import.
Hospital overdue payments (药款拖欠)
Long hospital payment cycles create cash stress that distributors try to push upstream. Tools include: contractual payment waterfalls, guarantee structures, stop-supply rights (mind tender supply duties), negotiation via hospital groups, and litigation/arbitration with preservation of assets. General commercial recovery patterns on this site can be verticalised with tender and quality-file evidence.
Playbook for in-house counsel
- Within 14 days of award: inventory map + margin model + clause heat-map on every active distributor agreement.
- Issue a written allocation policy for tender vs non-tender SKUs to avoid oral “pressures” that become lawsuit exhibits.
- Align medical affairs / quality holds with commercial stop-ship decisions—do not create a false quality story for channel reasons.
- If termination is inevitable, script notice, inventory count protocol, and seal-sample retention the same day.
Related
Cluster hub · Anti-corruption · Device licensing
FAQ · 高频检索问题
Chinese long-tail intents mapped to this guide (orientation only).
集采中标后经销商压货退货怎么处理？
弃标会不会进黑名单？
医院拖欠药款如何催收？
Need sector counsel?
Map your issue to a specialty desk: Life sciences & healthcare · Devices & IVD · Clinical & health data · Product liability · Industry hub.
Find counsel
